Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840460 | 0.91 | TDP1 (0.37) | KCNMA1MAPTTDP1POLBMAPK1 | |
| SCHEMBL4837176 | 0.88 | HTT (0.38) | ALDH3A1MAPTTDP1POLBMAPK1 | |
| SCHEMBL6993884 | 0.87 | EPAS1 (0.43) | KCNMA1ALDH3A1MAPTTDP1POLB | |
| SCHEMBL4839033 | 0.86 | MAPK1 (0.47) | KCNMA1MAPTPOLBMAPK1ALDH1A1 | |
| SCHEMBL4879805 | 0.86 | MAPK1 (0.46) | MAPTTDP1MAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL7000491 | 0.82 | ATM (0.38) | KCNMA1ALDH3A1MAPTTDP1POLB | |
| SCHEMBL6998222 | 0.78 | IDO1 (0.39) | MAPTPOLBMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL6995064 | 0.78 | KAT2B (0.36) | ALDH3A1MAPTTDP1POLBMAPK1 | |
| SCHEMBL11531612 | 0.76 | MAPK10 (0.52) | MAPTPOLBALDH1A1L3MBTL1MAPK10 | |
| SCHEMBL6992038 | 0.76 | L3MBTL1 (0.43) | MAPTTDP1MAPK1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| EP-1546134-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014895-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1016664-B1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6455521-B1 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6271225-B1 | PSYCHOLOGICAL DISORDERS | WELFIDE CORPORATION (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-1016664-A1 | FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042411-A1 | Condensed thiophene compounds and pharmaceutical use thereof | ACIN1, ACHE, TPMT | KCNMA1 2043/4885ALDH3A1 1304/4885MAPT 15/4885 |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | KCNMA1 408/4885ALDH3A1 388/4885MAPT 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.